The patented NuGenerex Immuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular , the Ii-Key ensures potent activation of CD4+ T cells , which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation.

Another article on T cells....GNBT's vaccine activates T cells!

https://norwalkreflector.com/news/271953/why-...new-study/


The findings also offer new insights that could help in developing a vaccine by looking at T cells, which help fight the virus.

Currently, all major candidates for a coronavirus vaccine undergoing clinical trials focus on harnessing a single antibody protein that can neutralize the virus